Korean Circ J.  2021 May;51(5):423-425. 10.4070/kcj.2021.0017.

Beginning the Journey to Find Optimal Antithrombotic Regimens for Korean Patients with Atrial Fibrillation after Percutaneous Coronary Intervention

• Kim SS
• Kim HK

• KMID: 2515765
• DOI: http://doi.org/10.4070/kcj.2021.0017

Figure

• 

  Figure 1 Key points to understand antithrombotic regimen in Korean patients with AF after PCI.This figure was modified from the original version.3)7)AF = atrial fibrillation; DAPT = dual antiplatelet therapy; OAC = oral anticoagulant; PCI = percutaneous coronary intervention.

Reference

1. Joung B, Lee JM, Lee KH, et al. 2018 Korean guideline of atrial fibrillation management. Korean Circ J. 2018; 48:1033–1080. PMID: 30403013.

2. Choi HI, Ahn JM, Kang SH, et al. Prevalence, management, and long-term (6-year) outcomes of atrial fibrillation among patients receiving drug-eluting coronary stents. JACC Cardiovasc Interv. 2017; 10:1075–1085. PMID: 28527773.

3. Kwon S, Jung JH, Choi EK, et al. Impact of non-vitamin K antagonist oral anticoagulants on the change of antithrombotic regimens in patients with atrial fibrillation undergoing percutaneous coronary intervention. Korean Circ J. 2021; 51:409–422.

4. Kim HK, Tantry US, Smith SC Jr, et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost. 2020; [Epub ahead of print].

5. Lee SH, Kim HK, Jeong MH, et al. Practical guidance for P2Y₁₂ inhibitors in acute myocardial infarction undergoing percutaneous coronary intervention. Eur Heart J Cardiovasc Pharmacother. 2020; [Epub ahead of print].

6. Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020; [Epub ahead of print].

7. Kupka D, Sibbing D. De-escalation of P2Y₁₂ receptor inhibitor therapy after acute coronary syndromes in patients undergoing percutaneous coronary intervention. Korean Circ J. 2018; 48:863–872. PMID: 30238704.

8. Kim HK, Tantry US, Gurbel PA, Jeong YH. Another unmet need against residual risk of atherosclerotic cardiovascular disease: can “Thrombin Pathway” be a new target for therapy? Korean Circ J. 2020; 50:817–821. PMID: 32812410.

9. Lopes RD, Leonardi S, Wojdyla DM, et al. Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial. Circulation. 2020; 141:781–783. PMID: 31707833.

10. Nakano M, Yahagi K, Otsuka F, et al. Causes of early stent thrombosis in patients presenting with acute coronary syndrome: an ex vivo human autopsy study. J Am Coll Cardiol. 2014; 63:2510–2520. PMID: 24768883.